November 3, 2026 | In the News | Forbes Mammogen has been featured in Forbes in an article by Geri Stengel exploring the company's mission to transform breast cancer detection through innovative RNA-based blood testing. The feature highlights Mammogen's co-founder and CEO, Elizabeth Cormier-May, and her vision for making earlier breast cancer detection more accessible, particularly for women with dense breast tissue. At the center of the story is genTRU-breast™ , Mammogen's investigational blood-based diagnostic designed to complement existing breast imaging and provide additional biological insights that may help inform clinical decisions. The Forbes article also explores Mammogen's Series A financing of up to $30 million, its approach to affordability and patient access, and its ongoing commitment to prospective clinical validation. A major focus is the KATELYN-ERIN clinical study, designed to enroll approximately 2,600 women to further evaluate the performance of genTRU-breast™. As Mammogen continues advancing its technology toward clinical integration, the Forbes feature brings attention to an important challenge in women's health: improving access to meaningful information that can support earlier detection and more informed care. Read the full Forbes feature: Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test Originally published by Forbes on November 3, 2026. Written by Geri Stengel. This summary was independently prepared by Mammogen. genTRU-breast™ is under clinical development, and prospective validation is ongoing.

BioSpace | October 20, 2026